Letters
Bovine spongiform encephalopathy threatens drugs in European Union
BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7105.426 (Published 16 August 1997) Cite this as: BMJ 1997;315:426
- Alan Earl-Slater, Senior lecturer in health economicsa
- a Keele University, Department of Medicines Management, Keele, Staffordshire ST5 5BG
Editor—While the debates about bovine spongiform encephalopathy periodically have a high profile in public health, food safety, and agricultural and political environments, the pharmaceutical environment is now becoming seriously entangled in the web of controversy. On 20 February this year the pharmaceutical council of the European parliament accepted the European Commission's proposed revisions to directive 75/18/EEC.
If the revisions are accepted by the European Union's Council of Ministers it will mean that drugs …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.